© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 22, 2020
The economic impact of the pandemic, which is still taking shape, will likely lead
to many patients being uninsured, resulting in less access to medical care and ultimately culminating in an uptick in cancer-related mortality in the years ahead.
October 25, 2020
The CLOVER-1 study is testing CLR 131 in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
September 15, 2020
Arjun V. Balar, MD, reviewed the data from the KEYNOTE-057 and how they impact the treatment of urothelial cancer in an editorial note.
August 16, 2020
Much of the most important work that must be done during the development of a new cancer medication is often accomplished long after FDA approval, wrote Arjun V. Balar, MD.